Berlex Climara Pro Gains Osteoporosis Prevention Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Berlex also updates labeling for the hormone replacement therapy to include new class labeling recommended by FDA.
You may also be interested in...
Vivelle-Dot Gains Despite Flagging Hormone Therapy Market
Sometimes bigger isn’t better; Noven says that the small size of its transdermal patch may be impetus for success.
Vivelle-Dot Gains Despite Flagging Hormone Therapy Market
Sometimes bigger isn’t better; Noven says that the small size of its transdermal patch may be impetus for success.
Berlex' Angeliq Approved, Will Launch In Mid-2006
The hormone therapy launch will be delayed to allow for physician education and to give the company time to consider internal resource issues as well as near-term pipeline opportunities, Berlex said.